Multiple Endocrine Neoplasia Type 2a
"Multiple Endocrine Neoplasia Type 2a" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A form of multiple endocrine neoplasia characterized by the presence of medullary carcinoma (CARCINOMA, MEDULLARY) of the THYROID GLAND, and usually with the co-occurrence of PHEOCHROMOCYTOMA, producing CALCITONIN and ADRENALINE, respectively. Less frequently, it can occur with hyperplasia or adenoma of the PARATHYROID GLANDS. This disease is due to gain-of-function mutations of the MEN2 gene on CHROMOSOME 10 (Locus: 10q11.2), also known as the RET proto-oncogene that encodes a RECEPTOR PROTEIN-TYROSINE KINASE. It is an autosomal dominant inherited disease.
| Descriptor ID |
D018813
|
| MeSH Number(s) |
C04.588.322.400.505 C04.651.600.505 C04.700.630.505 C16.320.700.630.505 C19.344.400.505
|
| Concept/Terms |
Multiple Endocrine Neoplasia Type 2a- Multiple Endocrine Neoplasia Type 2a
- MEA II
- MEA IIa
- MEN 2
- MEN 2a
- MEN II
- MEN IIa
- MEN-2A Syndrome
- MEN 2A Syndrome
- MEN-2A Syndromes
- MEN2a
- Multiple Endocrine Neoplasia Type 2
- Multiple Endocrine Neoplasms Type 2a
- Neoplasia, Multiple Endocrine Type 2a
- Neoplasms, Multiple Endocrine Type 2a
- Pheochromocytoma And Amyloid-Producing Medullary Thyroid Carcinoma
- Pheochromocytoma And Amyloid Producing Medullary Thyroid Carcinoma
- Sipple Syndrome
- Multiple Endocrine Neoplasia, Type IIa
- MEA 2a
|
Below are MeSH descriptors whose meaning is more general than "Multiple Endocrine Neoplasia Type 2a".
Below are MeSH descriptors whose meaning is more specific than "Multiple Endocrine Neoplasia Type 2a".
This graph shows the total number of publications written about "Multiple Endocrine Neoplasia Type 2a" by people in this website by year, and whether "Multiple Endocrine Neoplasia Type 2a" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 4 | 0 | 4 |
| 1996 | 4 | 2 | 6 |
| 1997 | 2 | 1 | 3 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 1 | 2 |
| 2001 | 3 | 0 | 3 |
| 2002 | 1 | 0 | 1 |
| 2003 | 2 | 2 | 4 |
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 2 | 0 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 3 | 0 | 3 |
| 2017 | 5 | 0 | 5 |
| 2018 | 1 | 1 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
| 2024 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Multiple Endocrine Neoplasia Type 2a" by people in Profiles.
-
Pediatric Medullary Thyroid Carcinoma: Clinical Presentations and Long-Term Outcomes in 144 Patients Over 6 Decades. J Clin Endocrinol Metab. 2024 Aug 13; 109(9):2256-2268.
-
RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions. Ann Endocrinol (Paris). 2024 Apr; 85(2):118-126.
-
Pheochromocytoma recurrence in hereditary disease: does a cortical-sparing technique increase recurrence rate? Surgery. 2023 Jan; 173(1):26-34.
-
The synergy of germline C634Y and V292M RET mutations in a northern Chinese family with multiple endocrine neoplasia type 2A. J Cell Mol Med. 2020 11; 24(22):13163-13170.
-
Surgical Management of Multiple Endocrine Neoplasia 1 and Multiple Endocrine Neoplasia 2. Surg Clin North Am. 2019 Aug; 99(4):693-709.
-
Genetic characterization of medullary thyroid cancer in childhood survivors of the Chernobyl accident. Surgery. 2019 01; 165(1):58-63.
-
A Homozygous RET K666N Genotype With an MEN2A Phenotype. J Clin Endocrinol Metab. 2018 04 01; 103(4):1269-1272.
-
Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib. Clin Cancer Res. 2018 02 15; 24(4):753-765.
-
Response to Letter: "Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness". J Clin Endocrinol Metab. 2017 09 01; 102(9):3559.
-
Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness. J Clin Endocrinol Metab. 2017 08 01; 102(8):2807-2813.